No Data
SpringWorks (SWTX) Completes NDA Submission for Mirdametinib
SpringWorks Therapeutics, Inc. (SWTX Quick QuoteSWTX - Free Report) announced that it has completed the submission of a new drug application (“NDA”) for its investigational MEK inhibitor, mirdametinib, being developed for the treatment of neurofibromatosis type 1- associated plexiform neurofibromas (NF1-PN), in pediatric and adult patients.
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Springworks Therapeutics (SWTX)
Barclays Issues a Buy Rating on Springworks Therapeutics (SWTX)
Sector Update: Health Care Stocks Mixed Premarket Monday
Health care stocks were mixed premarket Monday as the Health Care Select Sector SPDR Fund (XLV) was 0.3% higher and the iShares Biotechnology ETF (IBB) was down 0.2% recently. SpringWorks Therapeutics
Sector Update: Health Care
Health care stocks were flat to higher premarket Monday as the Health Care Select Sector SPDR Fund (XLV) was inactive and the iShares Biotechnology ETF (IBB) was up 0.4% recently. SpringWorks Therapeu
Express News | SpringWorks Therapeutics Inc - in H2 2024, Plans to File Marketing Authorization Application With EMA for Mirdametinib
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.
Rana Hasan1 : List too long